These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 11857958)

  • 21. Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy.
    Farnier M; Ducobu J; Bryniarski L
    Curr Med Res Opin; 2011 Nov; 27(11):2165-73. PubMed ID: 21973199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paradoxical exacerbation of combined hyperlipidemia in human apolipoprotein A-II transgenic mice treated with fenofibrate.
    Ribas V; Palomer X; Roglans N; Rotllan N; Fievet C; Tailleux A; Julve J; Laguna JC; Blanco-Vaca F; Escolà-Gil JC
    Biochim Biophys Acta; 2005 Dec; 1737(2-3):130-7. PubMed ID: 16226489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of fenofibrate therapy on renal function in primary gout patients.
    Li X; Sun W; Lu J; He Y; Chen Y; Ren W; Cui L; Liu Z; Wang C; Wang X; Ma L; Cheng X; Han L; Li H; Zhang H; Yuan X; Ji X; Ji A; Merriman TR; Li C
    Rheumatology (Oxford); 2021 Nov; 60(11):5020-5027. PubMed ID: 33704429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fenofibrate-induced cirrhosis.
    Ahmed F; Petrovic L; Rosen E; Gonzalez R; Jacobson IM
    Dig Dis Sci; 2005 Feb; 50(2):312-3. PubMed ID: 15745090
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of fenofibrate on biliary lipids and bile acid pool size in patients with type IV hyperlipoproteinemia.
    Podda M; Zuin M
    Atherosclerosis; 1985 May; 55(2):135-42. PubMed ID: 4004987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fenofibrate-induced acute renal failure due to massive rhabdomyolysis after coadministration of statin in two patients.
    Unal A; Torun E; Sipahioglu MH; Tokgoz B; Kaya MG; Oymak O; Utas C
    Intern Med; 2008; 47(11):1017-9. PubMed ID: 18520113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration.
    Mayer O; Simon J; Holubec L; Pikner R; Subrt I
    Eur J Clin Pharmacol; 2003 Sep; 59(5-6):367-71. PubMed ID: 12845504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients.
    Forcheron F; Cachefo A; Thevenon S; Pinteur C; Beylot M
    Diabetes; 2002 Dec; 51(12):3486-91. PubMed ID: 12453904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fenofibrate increases creatininemia by increasing metabolic production of creatinine.
    Hottelart C; El Esper N; Rose F; Achard JM; Fournier A
    Nephron; 2002; 92(3):536-41. PubMed ID: 12372935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate.
    Dierkes J; Westphal S; Kunstmann S; Banditt P; Lössner A; Luley C
    Atherosclerosis; 2001 Sep; 158(1):161-4. PubMed ID: 11500187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Association of Fenofibrate with Kidney Tubular Injury in a Subgroup of Participants in the ACCORD Trial.
    Chauhan K; Nadkarni GN; Debnath N; Chan L; Saha A; Garg AX; Parikh CR; Coca SG
    Clin J Am Soc Nephrol; 2019 Oct; 14(10):1521-1523. PubMed ID: 31409596
    [No Abstract]   [Full Text] [Related]  

  • 32. Pleiotropic effects of fenofibrate therapy on rats with hypertriglycemia.
    Sun B; Xie Y; Jiang J; Wang Y; Xu X; Zhao C; Huang F
    Lipids Health Dis; 2015 Apr; 14():27. PubMed ID: 25890112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Liver function tests: analysis of biliary tract enzymes and serum secretory enzymes--ALP, gamma-GTP, LAP, and ChE].
    Fujisawa K
    Rinsho Byori; 1986 Jun; 34 Spec No 67():42-50. PubMed ID: 2877107
    [No Abstract]   [Full Text] [Related]  

  • 34. A Case of Fenofibrate-Induced Immune Thrombocytopenia: First Report.
    Agapakis DI; Massa EV
    P R Health Sci J; 2015 Sep; 34(3):170-3. PubMed ID: 26356743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preventive effects of fenofibrate on insulin resistance, hyperglycaemia, visceral fat accumulation in NIH mice induced by small-dose streptozotocin and lard.
    Xie W; Nie Y; Du L; Zhang Y; Cai G
    Pharmacol Res; 2007 May; 55(5):392-9. PubMed ID: 17306985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term use of fenofibrate is associated with increased prevalence of gallstone disease among patients undergoing maintenance hemodialysis.
    Liang CC; Wang IK; Kuo HL; Yeh HC; Lin HH; Liu YL; Hsu WM; Huang CC; Chang CT
    Ren Fail; 2011; 33(5):489-93. PubMed ID: 21574895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity.
    Kostapanos MS; Athyros VG; Mikhailidis DP; Elisaf MS
    J Clin Lipidol; 2013; 7(1):88. PubMed ID: 23351588
    [No Abstract]   [Full Text] [Related]  

  • 39. Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use.
    Holoshitz N; Alsheikh-Ali AA; Karas RH
    Am J Cardiol; 2008 Jan; 101(1):95-7. PubMed ID: 18157972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fenofibrate in the treatment of dyslipidemia associated with HIV infection.
    Samineni D; Fichtenbaum CJ
    Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):995-1004. PubMed ID: 20604734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.